Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 17/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.66 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.66 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.66 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.61 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10243749 | 0.95 | SYK (0.67) | SYKKCNH2AURKBZAP70EGFR | |
| SCHEMBL763221 | 0.93 | SYK (0.67) | SYKKCNH2AURKBZAP70MAPK8 | |
| SCHEMBL10241903 | 0.90 | SYK (0.70) | SYKKCNH2AURKBZAP70MAPK8 | |
| SCHEMBL14659023 | 0.90 | SYK (0.72) | SYKKCNH2AURKBZAP70MAPK8 | |
| SCHEMBL29761550 | 0.90 | SYK (0.72) | SYKKCNH2AURKBZAP70MAPK8 | |
| SCHEMBL763269 | 0.89 | SYK (0.69) | SYKKCNH2AURKBZAP70MAPK8 | |
| SCHEMBL15161258 | 0.89 | SYK (0.69) | SYKKCNH2AURKBZAP70MAPK8 | |
| SCHEMBL763608 | 0.89 | STAT6 (0.73) | SYKKCNH2AURKBZAP70MAPK8 | |
| SCHEMBL915061 | 0.88 | EGFR (0.67) | SYKKCNH2AURKBZAP70MAPK8 | |
| SCHEMBL2493850 | 0.87 | SYK (0.72) | SYKKCNH2AURKBZAP70 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937070-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-01-20 | — | — | US | disclosed |
| US-20140031361-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. | 2014-01-30 | — | — | US | disclosed |
| US-8501944-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8138339-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318407-A1 | Inhibitors of protein kinases | SYK, BTK, JAK1 | SYK 1/4885KCNH2 3335/4885AURKB 511/4885 |
| US-20140031361-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK1 | SYK 1/4885KCNH2 3335/4885AURKB 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.